Casaasdas

A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).

Por um escritor misterioso
Last updated 03 março 2025
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study - Pavelka - 2020 - ACR Open Rheumatology - Wiley Online Library
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. - Abstract - Europe PMC
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
IJMS, Free Full-Text
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified by sex, Arthritis Research & Therapy
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
TNF‐alpha inhibitors for ankylosing spondylitis - Maxwell, LJ - 2015
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy - ScienceDirect
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
TNF Inhibitor Therapy, Ankylosing Spondylitis
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
TNF Inhibitor Therapy, Ankylosing Spondylitis
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Mean (A) ASDAS and (B) BASDAI up to Week 48. Safety Set (N=89).
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Monthly improvements in paid work productivity: ankylosing spondylitis
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial - The Lancet
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Full article: POSTER PRESENTATIONS
Recomendado para você
você pode gostar

© 2014-2025 phtarkwa.com. All rights reserved.